Mga Batayang Estadistika
| LEI | 549300Y5PR6RJR1STI24 |
| CIK | 1661059 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NextCure, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-523 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231 |
|
| August 7, 2025 |
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results – Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter – Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers – Plan to provide SIM0505 and LNCB74 progra |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| August 7, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) is made effective on June 13, 2025 (the “Effective Date”), by and between NextCure, Inc., a Delaware |
|
| July 29, 2025 |
Up to 338,636 Shares of Common Stock Offered by the Selling Stockholder NEXTCURE, INC. Common Stock TABLE OF CONTENTS Pursuant to Rule 424(b)(2) Registration No. 333-288763 PROSPECTUS Up to 338,636 Shares of Common Stock Offered by the Selling Stockholder NEXTCURE, INC. Common Stock This prospectus relates to the resale, from time to time by the selling stockholder named in this prospectus (the “selling stockholder”) of up to 338,636 shares of our common stock (the “Shares”) (as adjusted for t |
|
| July 28, 2025 |
9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 Tel : (240) 399-4900 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 Tel : (240) 399-4900 July 28, 2025 Via EDGAR U. |
|
| July 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NextCure, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Num |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| July 14, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXTCURE, INC. NextCure, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows: FIRST: The name of the Corporation is NextCure, Inc. The Corporation’s original Certificate of Incorpor |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| June 23, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| June 16, 2025 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Subscription Agreement”) is dated as of June 13, 2025 (the “Execution Date”), by and between NextCure, Inc., a Delaware corporation (the “Company”), and Simcere Zaiming, Inc., a Delaware corporation (the “Subscriber”). The Company and the Subscriber are sometimes referred to herein as the “Parties.” RECITALS A. WHEREAS, concurr |
|
| June 16, 2025 |
Exhibit 99.2 NASDAQ: NXTC SIM0505 LNCB74 J U N E 2 0 2 5 Corporate Presentation Forward-Looking Statements 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions a |
|
| June 16, 2025 |
Exhibit 99.1 NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights - Phase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025 - Initial Phase 1 clinical data is |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| June 16, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 13, 2025, by and among NextCure, Inc., a Delaware corporation (the “Company”), and Simcere Zaiming, Inc., a Delaware corporation (the “Investor”). This Agreement is made in connection with the Subscription Agreement (the “Subscription Agreement”), dated as of the dat |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| May 1, 2025 |
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports First Quarter 2025 Financial Results – Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 – Plan to provide a proof of concept data readout in the first half of 2026 – Cash of approximately $55.9 million expected to fund operations into the second |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231247 |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| April 15, 2025 |
TABLE OF CONTENTS PRELIMINARY COPY — SUBJECT TO COMPLETION — DATED APRIL 15, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231 |
|
| April 10, 2025 |
Exhibit 99.1 Corporate Presentation NASDAQ: NXTC APRIL 2025 Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| March 6, 2025 |
NextCure Provides Business Update and Reports Full Year 2024 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Full Year 2024 Financial Results – Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025 – Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md. – March 6, 2025 – NextCure, Inc |
|
| March 6, 2025 |
Exhibit 10.32 February 12, 2025 Via Email Only Udayan Guha, M.D., Ph.D. c/o NextCure, Inc. 9000 Virginia Manor Rd., Suite 200 Beltsville, MD 20705 RE:EXECUTIVE EMPLOYMENT AGREEMENT Dear Dr. Guha: On behalf of NextCure, Inc. (“NextCure”, or the “Company”), it is my pleasure to confirm your promotion to Chief Medical Officer, effective February 1, 2025. As a result of your promotion, this letter set |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001- |
|
| March 6, 2025 |
NextCure, Inc. Trading Compliance Policy Exhibit 19 NEXTCURE, INC. TRADING COMPLIANCE POLICY Effective May 2, 2023 NextCure, Inc. (the “Company”) has adopted this Trading Compliance Policy (this “Policy”) to set forth the Company’s standards on trading, and causing the trading of, the Company’s securities or securities of certain other publicly-traded companies while in possession of confidential information. For purposes of this Policy, |
|
| February 14, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with |
|
| February 3, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52 |
|
| January 10, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52 |
|
| January 10, 2025 |
Exhibit 99.1 NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers BELTSVILLE, Md. – January 10 , 2025 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has be |
|
| December 10, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5 |
|
| December 10, 2024 |
NextCure Announces Acceptance of IND Application for LNCB74 Exhibit 99.1 NextCure Announces Acceptance of IND Application for LNCB74 – LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences BELTSVILLE, Md. – December 10 , 2024 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class t |
|
| December 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52 |
|
| December 5, 2024 |
Exhibit 99.1 Corporate Presentation NASDAQ: NXTC DECEMBER 2024 Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other informati |
|
| November 14, 2024 |
NXTC / NextCure, Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 nxtc13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) NextCure, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 65343E108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 13, 2024 |
NXTC / NextCure, Inc. / Affinity Asset Advisors, LLC - AMENDMENT TO SCHEDULE 13G Passive Investment SC 13G/A 1 nextcure-sc13ga093024.htm AMENDMENT TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NextCure, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 65343E 108 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 |
|
| November 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52 |
|
| November 8, 2024 |
Exhibit 99.1 Corporate Presentation NASDAQ: NXTC NOVEMBER 2024 Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other informati |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Num |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52 |
|
| November 7, 2024 |
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results – Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end – Cash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md. – November 7, 2024 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committ |
|
| August 1, 2024 |
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results – LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-end – NC410 combo with pembrolizumab ovarian cohort enrollment completed – Cash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md. – August 1, 2024 – NextCure, Inc. ( |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231 |
|
| June 27, 2024 |
NXTC / NextCure, Inc. / Affinity Asset Advisors, LLC - SCHEDULE 13G Passive Investment SC 13G 1 nextcure-sc13g062024.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NextCure, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 65343E 108 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 Third Avenue, 20t |
|
| June 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| June 18, 2024 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] SCIENTIFIC ADVISORY AND CONSULTING AGREEMENT This Scientific Advisory and Consulting Agreement (this “Agreement”) dated July 2, 2024, (the “Effective Date”) is |
|
| May 2, 2024 |
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports First Quarter 2024 Financial Results – Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 – Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting – Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE, Md. – May 2, 2024 – NextC |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231247 |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| April 16, 2024 |
TABLE OF CONTENTS PRELIMINARY COPY — SUBJECT TO COMPLETION — DATED APRIL 16, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 1, 2024 |
NXTC / NextCure, Inc. / Logos Global Management LP Passive Investment SC 13G 1 nxtc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) NextCure, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 65343E108 (CUSIP Number) April 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| March 21, 2024 |
Exhibit 99.2 Corporate Presentation NASDAQ: NXTC MARCH 2024 Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001- |
|
| March 21, 2024 |
Exhibit 10.30 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***] RESEARCH COLLABORATION AND Co-Development AGREEMENT BY AND BETWEEN NextCure, INc. AND LEGOCHEM BIOSCIENCES, INC. NOVEMBER 9, 2022 - 1 - RESEARCH COLLABORATION |
|
| March 21, 2024 |
NextCure Provides Business Update and Reports Full Year 2023 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Full Year 2023 Financial Results – Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC) – Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts with data updates in 2024 – LNCB74, in collaboration with LegoChem, planned filing of an IND by year-en |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231 |
|
| March 21, 2024 |
NextCure, Inc. Policy on Recoupment of Incentive Compensation. Exhibit 97 NextCure, Inc. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of NextCure, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatem |
|
| March 8, 2024 |
EX-99.1 2 ss3118746ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to the Statement on Schedule 13D, dated March 6, 2024, with respect to the common stock of NextCure, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Eac |
|
| March 8, 2024 |
NXTC / NextCure, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) NextCure, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 65343E108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone |
|
| January 19, 2024 |
NXTC / NextCure, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) NEXTCURE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 65343E108 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| December 14, 2023 |
NextCure Provides Year-End Clinical Pipeline Updates Exhibit 99.1 NextCure Provides Year-End Clinical Pipeline Updates BELTSVILLE, Md. – December 14, 2023 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline. NC410 (LAIR-2 fusion) ● The Phase 1b combi |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Num |
|
| November 2, 2023 |
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results – Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year end – Cash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md. – November 2, 2023 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committ |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52 |
|
| August 9, 2023 |
[Signature Page Immediately Follows] August 9, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Dillon Hagius Re: Acceleration Request for NextCure, Inc. Registration Statement on Form S-3 (File No. 333-273723) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, NextCure, Inc. (the “Company”), hereby re |
|
| August 4, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) NextCure, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Common Stock, $0.001 par v |
|
| August 4, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NextCure, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 4, 2023 |
Exhibit 1.2 NEXTCURE, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT August 4, 2023 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: NextCure, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance and Sale |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NextCure, Inc. |
|
| August 3, 2023 |
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results – Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023 – Cash of approximately $131 million expected to fund operations into mid-2025 BELTSVILLE, Md. – August 3, 2023 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company com |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231 |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2023 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 26, 2023 |
Exhibit 3.1 Adopted June 22, 2023 Second AMENDED AND RESTATED BYLAWS OF Nextcure, Inc. ARTICLE I Offices Section 1.01 Registered Office. The registered office of NextCure, Inc. (the “Corporation”) will be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section 1.02 Other Offices. The |
|
| May 4, 2023 |
Exhibit 10.1 SIXTH AMENDMENT TO LEASE AGREEMENT This SIXTH AMENDMENT TO LEASE AGREEMENT (“this Sixth Amendment”) is dated as of April 19, 2023 (“Effective Date”), by and between ARE-8000/9000/10000 VIRGINIA MANOR, LLC, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 (“Landlord”), and NEXTCURE, INC., a Delaware corporation, having an add |
|
| May 4, 2023 |
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports First Quarter 2023 Financial Results – Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs – First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1 trial in acute myeloid leukemia (AML) – Cash of approximately $145 million expected to fund operations into mid-2025 BELTSVILLE, Md. – May 4, 2023 – NextCure, Inc. (Na |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-5231247 |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| April 4, 2023 |
Up to $16,638,677 Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-241706 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated May 6, 2021 (To the Prospectus dated March 12, 2021) Up to $16,638,677 Common Stock This prospectus supplement, amends and supplements the prospectus supplement, dated May 6, 2021, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 |
|
| March 2, 2023 |
Exhibit 10.30 February 28, 2023 Via Email Only Kevin G. Shaw [***] RE:EXECUTIVE EMPLOYMENT AGREEMENT Dear Mr. Shaw: On behalf of NextCure, Inc. (“NextCure”, or the “Company”), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure (the “Board”) and you have agreed that you will continue your employment with the Company, serving as the Company’s Senior Vic |
|
| March 2, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 2, 2023 |
Exhibit 10.28 THIRD AMENDMENT TO SRA This THIRD AMENDMENT TO SRA (this “THIRD AMENDMENT”) is made and entered into effective as of September 14, 2022 (“THIRD AMENDMENT EFFECTIVE DATE”) by and between Yale University, a nonprofit corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut (“YALE”), and NextCure, Inc., a |
|
| March 2, 2023 |
NextCure Provides Business Update and Reports Full Year 2022 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Full Year 2022 Financial Results – Clinical data updates expected in 2023 for all three programs – NC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML) – Ended 2022 with approximately $160 million in cash that is expected to fund operations into mid-2025 BELTSVILLE, Md. – March 2, 2023 – NextCure, Inc. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52312 |
|
| March 2, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001- |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Nextcure, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| January 24, 2023 |
NXTC / NextCure Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 NXTCSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NEXTCURE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 65343E108 (CUSIP Number) JANUARY 19, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38905 (Commission File Number) 47-52 |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Num |
|
| November 3, 2022 |
NextCure Provides Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 ? NextCure Provides Update and Reports Third Quarter 2022 Financial Results ? Discontinuing development of our NC318 program ? Advancing clinical pipeline: NC410 combination, NC525, and NC762 ? Extending runway into mid-2025 (an additional 15 months) ? BELTSVILLE, Md. ? November 3, 2022 ? NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discoverin |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2022 |
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results ? On track to report data from all three clinical programs ? Second quarter ending cash of $185.5 million expected to fund operations into the first quarter of 2024 BELTSVILLE, Md. ? August 4, 2022 ? NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 5, 2022 |
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports First Quarter 2022 Financial Results – On track to report data from all three clinical programs in the second half of 2022 – First quarter ending cash of $201.3 million expected to fund operations into the first quarter of 2024 BELTSVILLE, Md. – May 5, 2022 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committ |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| March 3, 2022 |
? Exhibit 10.24 ? ? May 11, 2021 ? Via Email Only ? Han Myint, M.D. [***] ? RE:EXECUTIVE EMPLOYMENT AGREEMENT ? Dear Dr. Myint: ? On behalf of NextCure, Inc. (?NextCure?, or the ?Company?), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure (the ?Board?) and you have agreed that you will continue your employment with the Company, serving as the Compan |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 3, 2022 |
Exhibit 10.23 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***]. ? SECOND AMENDMENT TO LICENSE AGREEMENT AND SRA ? THIS SECOND AMENDMENT TO LICENSE AGREEMENT AND SRA (this ?AMENDMENT?) is made and entered into, and effective, as of |
|
| March 3, 2022 |
Next Generation Immunomedicines March 2022 Exhibit 99.2 Next Generation Immunomedicines March 2022 PROPRIETARY AND CONFIDENTIAL 2 2 Forward - Looking Statements This presentation contains forward - looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . These statements are based on current expectations, forecasts, assumptions and other information available |
|
| March 3, 2022 |
? Exhibit 10.26 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***]. ? THIRD AMENDMENT TO LEASE AGREEMENT ? THIS THIRD AMENDMENT TO LEASE AGREEMENT (?this Third Amendment?) is dated as of February 4, 2022 (?Effective Date?), by and be |
|
| March 3, 2022 |
Exhibit 99.1 NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results ? Multiple data readouts expected in 2022, including updates for all three clinical programs ? Ends 2021 with cash position of $219.6 million that is expected to fund operations into first quarter of 2024 BELTSVILLE, Md. ? March 3, 2022 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage bi |
|
| March 3, 2022 |
Exhibit 10.25 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (?this Second Amendment?) is dated as of February 19, 2020 (?Effective Date?), by and between ARE-8000/9000/10000 VIRGINIA MANOR, LLC, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 (?Landlord?), and NEXTCURE, INC., a Delaware corporation, having |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nextcure, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 15, 2021 |
Exhibit 99.2 |
|
| November 15, 2021 |
Exhibit 99.1 NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting BELTSVILLE, Md. ? November 13, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related disease |
|
| November 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NextCure, Inc. |
|
| November 4, 2021 |
? Exhibit 10.1 AMENDMENT TO THE NEXTCURE, INC. 2015 OMNIBUS INCENTIVE PLAN This Amendment (the ?Amendment?) to the NextCure, Inc. 2015 Omnibus Incentive Plan, as amended on November 5, 2018 (the ?Plan?), is adopted by NextCure, Inc., a Delaware corporation (the ?Company?), to be effective as set forth below. RECITALS WHEREAS, Section 5.3 of the Plan allows the Board of Directors of the Company (th |
|
| November 4, 2021 |
Exhibit 99.1 NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update BELTSVILLE, Md. ? November 4, 2021 ? NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2021 financial results and provided |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NextCure, Inc. |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| October 4, 2021 |
NextCure Announces New Appointments to its Board of Directors Exhibit 99.1 NextCure Announces New Appointments to its Board of Directors BELTSVILLE, Md., October 4, 2021 ? NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to i |
|
| September 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
NextCure Reports Second Quarter 2021 Financial Results Exhibit 99.1 NextCure Reports Second Quarter 2021 Financial Results BELTSVILLE, Md. ? August 5, 2021 ? NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2021 financial results and provided a business update. ?We have |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 25, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 6, 2021 |
Sales Agreement, dated May 6, 2021, between the Company and SVB Leerink LLC. EX-1.1 2 tm2115384d1ex1-1.htm EXHIBIT 1.1 Exhibbit 1.1 NEXTCURE, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT May 6, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: NextCure, Inc, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 6, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2021 |
Up to $75,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(5) Registration No. 333-241706 PROSPECTUS SUPPLEMENT (to Prospectus dated March 12, 2021) Up to $75,000,000 Common Stock We have entered into a sales agreement with SVB Leerink LLC (“SVB Leerink”) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| April 29, 2021 |
Proxy Statement on Schedule 14A filed April 29, 2021, TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001- |
|
| April 26, 2021 |
NextCure, Inc., 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705 April 26, 2021 Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| March 5, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 4, 2021 Registration No. |
|
| March 4, 2021 |
As filed with the Securities and Exchange Commission on March 4, 2021 Registration No. |
|
| March 4, 2021 |
Exhibit 24.1 ? POWER OF ATTORNEY ? Each of the undersigned directors of NextCure, Inc., a Delaware corporation (the ?Corporation?), hereby constitutes and appoints Michael Richman and Steven P. Cobourn, and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power to them and each of them to sign for the undersigned, and in her or her name and in the capacity or |
|
| March 4, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| March 4, 2021 |
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results BELTSVILLE, Md. – March 4, 2021 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 fin |
|
| March 4, 2021 |
Exhibit 10.3 Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm to NextCure, Inc. if publicly disclosed. AMENDMENT TO LICENSE AGREEMENT AND SRA THIS AMENDMENT TO LICENSE AGREEMENT AND SRA (this ?AMENDMENT?) is made and entered into as of this 25th day of April 2020, to be effective as of January 31, 2020 |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NextCure Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 3, 2021 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each |
|
| February 3, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* NextCure, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 3, 2021 |
EX-24 Exhibit 24 2018 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor on the signature pages hereto (suc |
|
| January 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 14, 2021 |
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer Exhibit 99.1 Dr. Han Myint Appointed as NextCure’s Chief Medical Officer BELTSVILLE, Md. – January 14, 2021 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 or ◻ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Num |
|
| September 14, 2020 |
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors Exhibit 99.1 NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors BELTSVILLE, Md., September 14, 2020 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston, Ph.D., to |
|
| September 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 14, 2020 |
Exhibit 10.1 NEXTCURE, INC. Non-Employee Director Compensation PROGRAM This NextCure, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) sets forth the arrangements for compensation for members of the Board of Directors of the Company (the “Board”) who are not employees or consultants of the Company (the “Non-Employee Directors”). All compensation paid pursuant to thi |
|
| August 6, 2020 |
Exhibit 10.4 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made effective as of August 4, 2020 (the “Effective Date”), by and between NextCure, Inc., a Delaware corporation (“Company”), and Kevin Heller, M.D., a resident of the State of Maryland (“Consultant”). WHEREAS, Consultant is willing to provide to Company, on the terms and conditions hereof, the consulting services d |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 or ◻ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| August 6, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 6, 2020 Registration No. |
|
| August 6, 2020 |
Exhibit 4.3 INDENTURE DATED AS OF , 20 BETWEEN NEXTCURE, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section 1.04 Acts of Holders; Re |
|
| July 31, 2020 |
Exhibit 10.1 July 20, 2020 Via Email Only Michael Richman 13503 Sanderling Place Germantown, MD 20874 RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Michael: On behalf of NextCure, Inc. (“NextCure”, or the “Company”), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure (the “Board”) and you have agreed that you will continue your employment with the Company, |
|
| July 31, 2020 |
Exhibit 10.3 July 20, 2020 Via Email Only Solomon Langermann, Ph.D. 6606 Cross Country Boulevard Baltimore, MD 21215 RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Sol: On behalf of NextCure, Inc. (“NextCure”, or the “Company”), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure (the “Board”) and you have agreed that you will continue your employment with th |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 31, 2020 |
Exhibit 10.2 July 20, 2020 Via Email Only Steven P. Cobourn 3904 Braveheart Circle Frederick, MD 21704 RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Steve: On behalf of NextCure, Inc. (“NextCure”, or the “Company”), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure (the “Board”) and you have agreed that you will continue your employment with the Company, s |
|
| July 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 13, 2020 |
EX-99.1 2 tm2022427d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer BELTSVILLE, Md. – July 13, 2020 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to trea |
|
| June 11, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 27, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 14, 2020 |
NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic Exhibit 99.1 NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic BELTSVILLE, Md., April 13, 2020 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the company's clinical trial acti |
|
| March 30, 2020 |
EX-99.1 2 tm2014023d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors BELTSVILLE, Md., March 30, 2020 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, to |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 12, 2020 |
NXTC / NextCure, Inc. 10-K - Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001- |
|
| March 12, 2020 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the end of the period covered by the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of NextCure, Inc. (“we” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), i |
|
| February 21, 2020 |
NXTC / NextCure, Inc. / GREAT POINT PARTNERS LLC - SCHEDULE 13G HOLDINGS REPORT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
NXTC / NextCure, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* NextCure, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2019 Date of Event Which Requires Filing |
|
| February 14, 2020 |
NXTC / NextCure, Inc. / LORD, ABBETT & CO. LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NextCure Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 14, 2020 |
NXTC / NextCure, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NextCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 13, 2020 |
NXTC / NextCure, Inc. / Lilly Asia Ventures Fund III, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Nextcure, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 6, 2020 |
EX-24 Exhibit 24 2018 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor on the signature pages hereto (suc |
|
| February 6, 2020 |
NXTC / NextCure, Inc. / CANAAN X L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* NextCure, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 65343E108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 6, 2020 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each |
|
| January 13, 2020 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2020 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2019 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 22, 2019 |
NXTC / NextCure, Inc. / Sofinnova Venture Partners IX, L.P. - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* NextCure, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 65343E108 (CUSIP Number) Nathalie Auber Sofinnova Investments, Inc. 3000 |
|
| November 19, 2019 |
NXTC / NextCure, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) NextCure, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 65343E108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone |
|
| November 19, 2019 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 19, 2019, with respect to the ordinary shares of NextCure, Inc. |
|
| November 18, 2019 |
NXTC / NextCure, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NextCure, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65343E108 (CUSIP Number) November 6, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 18, 2019 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 18, 2019, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D a |
|
| November 18, 2019 |
4,077,192 Shares NextCure, Inc. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS As of and for the Years Ended December 31, 2017 and 2018 Table of Contents Filed Pursuant to Rule 424(B)(4) Registration No. |
|
| November 14, 2019 |
QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on November 14, 2019 Registration No. |
|
| November 14, 2019 |
NXTC / NextCure, Inc. S-1MEF - - S-1MEF As filed with the Securities and Exchange Commission on November 14, 2019 Registration No. |
|
| November 12, 2019 |
Exhibit 10.1 Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm to NextCure, Inc. if publicly disclosed. FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (“this First Amendment”) is dated as of August 2, 2019 (“Effective Date”), by and between ARE-8000/9000/10000 VIRGINIA MANOR, |
|
| November 12, 2019 |
NXTC / NextCure, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Num |
|
| November 12, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS As of and for the Years Ended December 31, 2017 and 2018 Table of Contents As filed with the Securities and Exchange Commission on November 12, 2019 Registration No. |
|
| November 12, 2019 |
NXTC / NextCure, Inc. CORRESP - - November 12, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Gregory Dundas Re: NextCure, Inc. Registration Statement on Form S-1 (File No. 333-234639) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, please be advis |
|
| November 12, 2019 |
NXTC / NextCure, Inc. CORRESP - - NextCure, Inc. 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 November 12, 2019 VIA EDGAR U.S. Securities and Exchange Commission Office of Healthcare and Insurance Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NextCure, Inc. Registration Statement on Form S-1 File No. 333-234639 Acceleration Request Requested Date: Thursday, November 14, 2019 Reques |
|
| November 12, 2019 |
Form of Underwriting Agreement. Exhibit 1.1 [•] Shares NEXTCURE, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT , 2019 , 2019 Morgan Stanley & Co. LLC BofA Securities, Inc. Piper Jaffray & Co. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Piper Jaffray & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and |
|
| October 30, 2019 |
FIRST AMENDMENT TO LEASE AGREEMENT Exhibit 10.15 Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm to NextCure, Inc. if publicly disclosed. FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (“this First Amendment”) is dated as of August 2, 2019 (“Effective Date”), by and between ARE-8000/9000/10000 VIRGINIA MANOR |
|
| October 30, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS As of and for the Years Ended December 31, 2017 and 2018 Table of Contents Confidential Treatment Requested by NextCure, Inc. |
|
| October 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2019 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| October 2, 2019 |
NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer Exhibit 99.1 NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer Beltsville, Md. — October 2, 2019 — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the promotion of Timothy Mayer, Ph.D. from Senior V |
|
| August 12, 2019 |
NXTC / NextCure, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number 0 |
|
| August 12, 2019 |
EXHIBIT 31.2 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Steven P. Cobourn, certify that: 1. I have reviewed this quarterly report on Form 10-Q of NextCure, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 NextCure, Inc. (Exact name of registrant as specified in charter) Delaware 001-38905 47-5231247 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 10, 2019 |
NXTC / NextCure, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number |
|
| May 22, 2019 |
NXTC / NextCure, Inc. / PFIZER INC - SC 13G NEXTCURE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* NextCure, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 65343E 108 (CUSIP Number) May 13, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| May 21, 2019 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated May 17, 2019, with respect to the ordinary shares of NextCure, Inc. |
|
| May 21, 2019 |
NXTC / NextCure, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 NextCure, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 65343E108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone Number of Person A |
|
| May 17, 2019 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of NextCure, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigne |
|
| May 17, 2019 |
NXTC / NextCure, Inc. / CITADEL ADVISORS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* NextCure, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 65343E108 (CUSIP Number) May 9, 2019 Date of Event Which Requires Filing of the |
|
| May 17, 2019 |
NXTC / NextCure, Inc. / Sofinnova Venture Partners IX, L.P. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* NextCure, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 65343E108 (CUSIP Number) Nathalie Auber Sofinnova Investments, Inc. 3000 S |
|
| May 13, 2019 |
Exhibit 24.1 NEXTCURE, INC. POWER OF ATTORNEY The undersigned officers and directors of NextCure, Inc., a Delaware corporation (the “Company”), hereby constitute and appoint Michael Richman and Steven P. Cobourn, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and each of them, to sign for the |
|
| May 13, 2019 |
As filed with the Securities and Exchange Commission on May 13, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NextCure, Inc. |
|
| May 13, 2019 |
Form S-8 (Registration No. 333-231436) As filed with the Securities and Exchange Commission on May 13, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NextCure, Inc. |
|
| May 13, 2019 |
Exhibit 24.1 NEXTCURE, INC. POWER OF ATTORNEY The undersigned officers and directors of NextCure, Inc., a Delaware corporation (the “Company”), hereby constitute and appoint Michael Richman and Steven P. Cobourn, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and each of them, to sign for the |
|
| May 13, 2019 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NEXTCURE, INC. ARTICLE I Offices Section 1.01 Registered Office. The registered office of NextCure, Inc. (the “Corporation”) will be fixed in the Third Amended and Restated Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section 1.02 Other Offices. The Corp |
|
| May 13, 2019 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXTCURE, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NextCure, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. The name of the Cor |
|
| May 13, 2019 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 9, 2019 |
5,000,000 Shares NextCure, Inc. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. |
|
| May 8, 2019 |
As filed with the Securities and Exchange Commission on May 8, 2019. QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on May 8, 2019. |
|
| May 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 NextCure, Inc. (Exact name of registrant as specified in its charter) Delaware 47-5231247 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 9000 Virgi |
|
| May 6, 2019 |
NXTC / NextCure, Inc. CORRESP - - NextCure, Inc. 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 May 6, 2019 VIA EDGAR U.S. Securities and Exchange Commission Office of Healthcare and Insurance Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NextCure, Inc. Registration Statement on Form S-1 File No. 333-230837 Acceleration Request Requested Date: Wednesday, May 8, 2019 Requested Time: 4 |
|
| May 3, 2019 |
EX-3.4 2 a2238703zex-34.htm EX-3.4 Exhibit 3.4 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXTCURE, INC. May 3, 2019 Pursuant to the provisions of Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), NextCure, Inc., a Delaware corporation (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is NextCu |
|
| May 3, 2019 |
As filed with the Securities and Exchange Commission on May 3, 2019. Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on May 3, 2019. |
|
| April 29, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on April 29, 2019. |
|
| April 29, 2019 |
Forms of Stock Option Agreement under the NextCure, Inc. 2019 Omnibus Incentive Plan. Exhibit 10.9 Option No.: NEXTCURE, INC. 2019 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT COVER SHEET NextCure, Inc., a Delaware corporation (the ?Company?), hereby grants an option (the ?Option?) to purchase shares of its common stock, par value $0.001 (the ?Stock?), to the individual named below as Grantee, subject to the vesting and other conditions set forth below. The terms and con |
|
| April 29, 2019 |
Exhibit 10.11 Grant No.: NEXTCURE, INC. 2019 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT COVER SHEET NextCure, Inc., a Delaware corporation (the ?Company?), hereby grants Restricted Stock Units (?RSUs?) for shares of its common stock, par value $0.001 (the ?Stock?), to the individual named below as Grantee, subject to the vesting and other conditions set forth in the attachment. Additio |
|
| April 29, 2019 |
Exhibit 10.12 NEXTCURE, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN NEXTCURE, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1. PURPOSE AND INTERPRETATION (a) The purpose of the NextCure, Inc. 2019 Employee Stock Purchase Plan is to encourage and to enable Eligible Employees of the Company and its Participating Affiliates, through after-tax payroll deductions or periodic cash contributions, to acquire propriet |
|
| April 29, 2019 |
Form of Underwriting Agreement. Exhibit 1.1 [?] Shares NEXTCURE, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT , 2019 , 2019 Morgan Stanley & Co. LLC Merrill Lynch, Pierce, Fenner & Smith Incorporated Piper Jaffray & Co. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 c/o Piper Jaffray & Co. |
|
| April 29, 2019 |
Exhibit 10.8 NEXTCURE, INC. 2019 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 8 3.1 Committee 8 3.1.1 Powers and Authorities 8 3.1.2 Composition of the Committee 8 3.1.3 Other Committees 8 3.1.4 Delegation by the Committee 9 3.2 Board 9 3.3 Terms of Awards 9 3.3.1 Committee Authority 9 3.3.2 Forfeiture; Recoupment 10 3.4 No Repricing Wit |
|
| April 29, 2019 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXTCURE, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NextCure, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. The name of the Cor |
|
| April 29, 2019 |
Exhibit 10.10 Grant No.: NEXTCURE, INC. 2019 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK AGREEMENT COVER SHEET NextCure, Inc., a Delaware corporation (the ?Company?), hereby grants shares of its common stock, par value $0.001 (the ?Stock?), to the individual named below as Grantee, subject to the vesting and other conditions set forth in the attachment. Additional terms and conditions of the grant are |
|
| April 29, 2019 |
Non-Employee Director Compensation Program. Exhibit 10.13 NEXTCURE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This NextCure, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) sets forth the arrangements for compensation for members of the Board of Directors of the Company (the ?Board?) who are not employees or consultants of the Company (the ?Non-Employee Directors?). All compensation paid pursuant to th |
|
| April 17, 2019 |
NXTC / NextCure, Inc. CORRESP - - Hogan Lovells US LLP Harbor East 100 International Drive Suite 2000 Baltimore, MD 21202 T +1 410 659 2700 F +1 410 659 2701 www. |
